

North East London Guidance for Safe Fasting During Ramadan

Date	Version	Committee/Group/Network	Role	Review Date
March 2023	1.0	Diabetes clinical Leads and specialists	Document consultation: Reviewed and provided expert feedback and comments	February 2024
March 2023	1.0	North East London Formulary & Pathways Group (NEL FPG)	Approved	February 2024

This document has been adapted from the Tower Hamlets, Newham and Waltham Forest (TNW) 'Fasting safely during Ramadan guidance v1.3' for use across NEL.

Authors/Editors				
Original author of the TNW guidance: Yasmine Korimbux (updated by Rahil Patel)				
Guidance adapted by the NEL Medicines Optimisation Task and Finish Group:				
 Bola Sotubo (Senior Transformation Manager, Medicines Optimisation) Rahil Patel (Senior Prescribing Advisor) Anh Vu (Joint Formulary Pharmacist) Imran Khan (QIPP Pharmacist) Yvonne Lim (Medicine Optimisation Pharmacist) 				



Introduction

This guidance is to support healthcare professionals to support patients with healthcare conditions during Ramadan. Ramadan is one of the most holy months in the Muslim calendar. During this period, Muslims will fast for <u>29-30 days</u> between the hours of sunrise and sunset depending on the geographical location and season of the year) and increase in spiritual and devotional acts such as prayer, giving to charity, and strengthening family ties. Ramadan is expected to begin on <u>22nd or 23rd March 2023 and ends on either the 20th or 21st April 2023</u>, depending on the sighting of the new moon. It helps if NHS frontline staff are aware of, and respect this important religious obligation, and how such beliefs may affect the different elements of care.

Exemptions from fasting

Fasting is <u>not</u> considered compulsory for certain groups:

- People who are acutely unwell or have a long-term condition that may be worsened by fasting (physical or mental)
- Those who are very frail
- Women who are pregnant or breastfeeding or menstruating
- Travellers

The British Islamic Medical Association (BIMA) has also undertaken a series of rapid evidence reviews to explore the effect of observing the fast of Ramadan with common health conditions and provide recommendations for health professionals. Patients with pre-existing conditions who intend to fast should be risk stratified considering age, frailty, previous experiences of fasting, and the number of medical conditions. See further information <u>here</u>. An approach to advising people with existing conditions about fasting has been published recently in the British Medical Journal, see <u>here</u>.

Fasting Safely During Ramadan

If a person is healthy with no pre-existing conditions, there is no evidence to suggest fasting is harmful to their health provided they are adequately hydrated in non-fasting hours.



Considerations:

- 1) Maintaining adequate hydration:
 - Longer, warmer days may present an increased risk of dehydration which can particularly affect people with existing medical problems such as diabetes, high blood pressure, heart disease/lung disease, pregnant or elderly. People fasting should be advised to;
 - ✓ Avoid long periods of time in the sun on a sunny day
 - ✓ Drink plenty of water during non-fasting hours
 - ✓ Reduce caffeinated drinks including tea, coffee, and sweet or fizzy drinks
 - ✓ Eat a balanced diet that includes low releasing energy foods at the start of the fast (Sehri) to help maintain energy levels. Eat appropriate portion meals and reduce carbohydrate content and use healthier cooking methods (e.g. baking rather than frying).

2) Dietary Recommendations

- Try to have the meal at Sehri (early morning) just before sunrise, not at midnight. This will spread out your energy intake more evenly and result in a more balanced blood glucose when fasting.
- Include fruits, vegetables, dhal, and yogurt in your meals at Iftar(evening) and Sehri.
- Limit fried foods e.g. paratha, puri, chevera, katlamas, fried kebabs, and Bombay mix.
- Water should be the first choice for quenching thirst, otherwise, choose sugar-free types of fizzy drinks, decaffeinated drinks, and cordials. Avoid adding sugar to hot drinks; use a sweetener where needed e.g. Canderel, Sweetex, Hermesetas.
- Fill up on starchy foods such as basmati rice, chapatti, and pitta bread before you begin the fast.

Food to Avoid	Alternative Foods
Deep fried foods e.g. pakoras, samosas, fried dumplings	Chickpeas, baked samosas, boiled dumplings
High sugar Indian sweets e.g. Ghulab, Rasgulla, Burfi, Balushahi, Baklawa, Mithai	Milk-based sweets and puddings, e.g. Rasmalai
High-fat cooked foods, e.g. oily curries, and pastries	Alternate with chapattis made without oil and baked or grilled meat and chicken. Make pastry at home and use a single layer.

3) Regular physical activity and light exercise during non-fasting hours where possible.



- 4) Taking medicines: Patients need to continue to take their medicines even when fasting, so they should be advised not to stop <u>unless</u> advised by a healthcare professional to do so.
 - Some medicines may need changing, which should be discussed with the healthcare professional supporting the patient's care. Doing this a few weeks, even months before Ramadan is prudent.
 - Some temporary changes may need to be made. These must be done on an individual case basis

The NHS patient resource <u>Ramadan health guide (mcb.org.uk)</u> independently produced by Communities in Action provides further information and advice.

Those who should not fast	Those who may consider	Comments/advice for those who wish to fast
	fasting	
Respiratory		
 Those experiencing an acute exacerbation of their chronic lung condition Severe Asthma/COPD Poorly controlled lung disease with a high risk of exacerbations /hospital admissions Those receiving immunosuppressants for active lung disease Those receiving anti-fibrotic therapy 	• Where the condition is controlled e.g. asthma/COPD with inhaler use	 Patients should continue with their regular medication. Inhalers are considered not to invalidate fasts, whereas, inhalation solutions e.g. Respimat[®] should be taken during non-fasting period. Patients should continue to monitor their symptoms and the frequency of reliever medication. Those advised to measure peak flows should continue doing so. Ensure a current self-management plan is available. Patients should ensure they have appropriate supplies of necessary medications including rescue packs of antibiotics and steroids and should be reminded to not share inhalers, spacer devices, or nebulizers. Advise patients that if they are worried about the timings of taking inhalers and fasting, this should be discussed with a healthcare professional (HCP). Those recovering from an exacerbation should not fast until they have fully recovered and consulted with their HCP. Additional information for patients Asthma UK information: https://www.rightbreathe.com/

Clinical health conditions and fasting



Cardiovascular			
 Moderate - severe heart failure Pulmonary hypertension Recent Acute Coronary Syndrome/myocardial infarction (<6 weeks) Cardiomyopathy Severe valvular disease Poorly controlled arrhythmias (as defined by the specialist) Drugs where timings are critical e.g. ticagrelor 	 Hypertension Stable angina Mild – moderate heart failure Supraventricular tachycardias Atrial Fibrillation Non-sustained ventricular tachycardia Intracardiac devices (pacemaker, ICD) Mild/mild-moderate valvular disease 	 Patients should continue to take all their regular medication. Hypertension - Monitor with home BP machines if available. Antiplatelets should be taken after the main meal. Drugs including diuretics may contribute to dehydration/acute kidney injury (AKI). Patients should be informed about following <u>sick day rules</u> and may need to review with a clinician to consider dose changes/alternatives. See NICE - AKI use of medicines in people with or at increased risk of AKI: https://www.nice.org.uk/advice/ktt17- Advise patients to discuss with a HCP where required to ensure medicine timings can be altered to be compatible with fasting times e.g. move from a twice-daily regime to once daily. DOACs: avoid >12 hours between taking twice a day anticoagulant (due to the risk of not achieving 24 hours of anticoagulation) Advise patients to seek advice if the condition worsens, or develops new symptoms or adverse effects. ACEI/ARBs/renin-angiotensin antagonists in light of COVID-19: The European Society of Cardiology, The Renal Association (UK), The Heart Failure Society of America, the American College of Cardiology, and the American Heart Association all recommend that patients taking the above medications should not stop taking these medications unless they are specifically asked to do so by their clinician. For more information, please visit: https://ukkidney.org/health-professionals/covid-19/ukka-resources/uk-kidney-association-statement-covid-19 Advice from British Heart Foundation BHF for patients (see here) Conditions such as heart failure can worsen if medication is not taken regularly or at increased risk of dehydration, your symptoms may become more severe. If you experience fluid building up in the ankles, breathlessness, and fatigue, it could be a sign you need to return to your normal medication routine. Therefore, it may not be appropriate to continue fasting.	



Chronic kidney disease		
 Acutely unwell patients CKD patients in stages 4-5 with eGFR<30 mL/min/1.73m² Patients on haemodialysis/peritoneal dialysis Polycystic kidney disease Patients requiring immunosuppression (e.g. renal transplant) CKD stage 3-5 patients with other co-morbidities or at risk of dehydration Nephrotic syndrome Patients whose treatment regimens are not stable and need regular monitoring 	Patients with stable disease	 Patients should continue taking their medicines as prescribed. Patients should maintain their normal diet and fluid intake. Patients should be informed of the importance of fluid intake overnight (1.5 to 2 litres for most people) to avoid dehydration. Patients should seek advice if the condition worsens, or develop new symptoms or adverse effects. Ramadan and Eid recipes for people living with CKD can be found <u>here.</u> Contact Details Community Renal Clinic 020 3594 1704 / 020 3594 1705 Muslim Chaplaincy Service (Barts Health) 020 3594 2070 Email address: Helen.rainey@bartshealth.nhs.uk BHNT.Communityrenalservice@nhs.net
 Type 1 diabetes Type 2 diabetes with sustained poor control within the last 12 months Type 2 diabetes with renal or cardiovascular co- morbidities Type 2 diabetes on insulin Having started SGLT2 within 4 weeks of Ramadan 	• Well-controlled type 2 diabetes	 Regular blood glucose monitoring during Ramadan is advised especially if on sulfonylureas or insulin. Patients are recommended to break their fast if their blood glucose is <5mmol/L or >16.7mmol/L at any time during the fast. All patients should follow the recommended sick day rules: https://www.england.nhs.uk/london/london-clinical-networks/our-networks/diabetes/diabetes-COVID-19-key-information/ Patients taking some medications (e.g. sulfonylureas) may need to adjust their dose and/or timings (e.g. three daily dosing to twice daily). Converting sulfonylureas to shorter-acting options (e.g. repaglinide) may be preferable during fasting to reduce the risk of hypoglycemia. Insulins require a dose reduction (e.g. short-acting/pre-mixed by 25-50%) and/or a change to timings. Medicines that do not require dose change (advice from diabetic consultant at Barts Health – Prof. Tahseen Chowdhury)



 Acute hyperglycaemic complications History of significant or recurrent hypoglycaemia episodes Hypoglycaemia unawareness Advanced macrovascular diabetic complications Chronic dialysis and CKD (eGFR <45%) Renal transplant Pregnancy in pre-existing 	 Metformin – if on BD dosing no need to change to OD (modified release) preparation. If TDS dosing, patients should miss out on the lunchtime dose. DDP4 inhibitors (Gliptins e.g. sitagliptin, linagliptin) GLP1 agonists (e.g. liraglutide, dulaglutide, semaglutide) SGLT2i (e.g. dapagliflozin, empagliflozin) – ideally, don't start within one month of or during Ramadan stable on it, do not stop it. Warn patients of signs of euglycaemic ketoacidosis (abdominal pain, nause or vomiting) – to seek medical advice. Medicines that require dose change (advice from diabetic consultant at Barts- Prof Tahseen) Sulfonylureas & repaglinide – half the usual morning dose and take at the start of the fast. Take the fusual dose when ending the fast.
 Acute illness Treatment with drugs that can affect cognitive function 	Type of InsulinAdvise and informationLong- orOD - NPH/detemir/glargine/degludec. Take at Iftar. Reduce dose by 15–30%intermediate-actingBD - NPH/detemir/glargine. Swap the usual dosing. Take the usual morning dosebasal insulinat Iftar. Reduce the evening dose by 50% and take at SehriRapid- or short-Take the normal dose at Iftar. Omit lunchtime dose. Reduce Sehri dose by 25–50%actingDose titration should be performed every 3 days and adjustments madeprandial/bolusaccording to BG levels.
	Premixed insulinOD – Take normal dose at Iftar BD – If the dose is usually higher in the morning, consider the higher dose at Iftar and the lower dose at Sehri. Take the usual morning dose at Iftar. Reduce the evening dose by 25–50% and take at Sehri TDS – Omit afternoon dose. Adjust Iftar and Sehri doses according to the blood glucose test
	Insulin pump Basal rate – Reduce dose by 20–40% in the last 3–4 hours of fasting. Increase dose by 0– 30% early after Iftar Bolus rate – Normal carbohydrate counting and insulin sensitivity principles apply



Patients should:
• Have sufficient insulin/oral hypoglycaemic medicines, and glucose monitoring (blood glucose strips or continuous glucose monitoring sensors) during this period.
Have emergency contact numbers of their specialist diabetes teams for advice.
Take their medicines as prescribed.
Maintain their normal diet and fluid intake during times of eating.
Be advised to have low GI (glycaemic index) foods.
• Seek advice if the condition worsens or develops new symptoms or adverse effects.
 Be assessed and receive appropriate education and instructions related to physical activity, meal planning, glucose monitoring, and dosage and timing of medications where appropriate.
Information for patients:
 Diabetes UK – Managing your diabetes in Ramadan. Click <u>here</u>.
 Diabetes UK advice on fasting and managing your diabetes during Ramadan and factsheet in English, Arabic, Bengali, and Urdu
Diabetes UK tips on healthy food and drink choices during Ramadan
• The Muslim Council of Great Britain has also produced some useful guidance on fasting whilst also living with diabetes. Download <u>here</u> .
Watch the IDF Diabetes and Ramadan animation: Know your risk before fasting <u>here</u>
Information for HCPs:
 Diabetes Ramadan Alliance (DAR) – Practical guidelines. Click <u>here</u>.
 International Diabetes Forum – diabetes and Ramadan. Click <u>here</u>.
CDEP's 20-minute Diabetes and Ramadan topic supports healthcare staff (requires login):
 identify the risk category for people with diabetes who wish to fast during Ramadan and empower them to do so safely through appropriate education and advice.



Gastrointes	tinal				
Patients	with established	Stable chronic liver	Patients should continue ta	king their medicines as prescribed.	
cirrhosis		disease without	Patients should maintain th	eir normal diet and fluid intake and l	be aware of signs of dehydration.
Patients	who are <6 months post	cirrhosis	Patients should seek advice	e if the condition worsens, or develop	new symptoms or adverse effects.
liver tran	splant	Stable inflammatory			
Patients	with symptomatic	bowel disease in	IBD – Advice from Gastroenter	ology Consultants at Royal London H	lospital
active inf disease	lammatory bowel	remissionStable peptic ulcer	 Most IBD medications can be normal during the month. 	pe taken either as an OD or BD prepa	ration and therefore can be taken as
Patients	with significant acute or	disease, reflux	• Some 5-ASA medications ar	re still prescribed as TDS or even QDS	, but these can safely be converted to
chronic d	liarrhoea / high output	oesophagitis, and	OD: there is good evidence	that once-daily dosing of 5ASAs is just	st as effective as more frequent doses in
ileostom	Ý	irritable bowel	IBD.		
Patients	on prednisolone at	syndrome	Medications that patients s	elf-inject such as Adalimumab, Ustek	inumab, Golimumab, and Methotrexate
 doses >20 	Omg per day		should be continued as should the intravenous infusions Infliximab & Vedolizumab (these are also available for SC self-administration).		
	IBD Helpline:				
			Location	Contact Number	Emails
			Homerton Healthcare NHS	Adult: 0208 5105906	Adult: <u>Huh-</u>
			Foundation Trust		tr.homertonibdcns@nhs.net
			Barking, Havering, and	Adult: 01708 435 000 ext 3090 or	Adult: <u>bhrut.ibdhelp@nhs.net</u>
			Redbridge University Trust	3673	
			Royal London and Mile End Hospital	Paediatric and young adults: 020 3594 0402	Adult: <u>bhnt.ibdhelpline@nhs.net</u>
					Paediatric and young adults:
					bartshealth.pibd.helpline@nhs.net
			Muslim Chaplaincy Service (Bar	ts Health): 02035942070	1
Neurologica	Il disease	·	·		
Any cond	lition predisposing to	History of	• The long fasts may not be c	compatible with medication regimens	involving more than one daily dosing.
		cerebrovascular	Patients are at risk of dehve	dration (e.g. anticholinergic drugs) an	d alterations to cleaning nattorns



respiratory complications e.g.	disease or MS (low-	
bulbar weakness, neuromuscular		See ABN guidance for the management of immunosuppression during COVID-19
disorders	Well-controlled	https://www.theabn.org/news/492925/ABN-guidance-on-COVID19-and-MS-therapies.htm
Myasthenia Gravis on regular	epilepsy with a	
pyridostigmine	medication regime	
MND	compatible with the	
• Poorly controlled epilepsy, on	length of fast	
multiple antiepileptic	Myasthenia gravis not	
medications,	requiring	
history of status epilepticus,	pyridostigmine	
regime incompatible with fasting	• Purely ocular migraine	
Parkinson's disease requiring		
regular levodopa		
Neurodegenerative disorders		
with cognitive impairment		
Rheumatology		
Active SLE with renal	Rheumatological	Patients should continue taking their medicines as prescribed.
involvement	conditions in remission	Patients should maintain their normal diet and fluid intake.
 Active vasculitis with renal 	e.g.	• Patients should seek advice if the condition worsens, or they develop new symptoms or adverse effects.
involvement	Rheumatoid arthritis	
 Low eGFR secondary to 	Polymyalgia	Rheumatoid arthritis
connective	Rheumatica	Modified-release preparations could be considered as the dosing interval might get longer while fasting, and
tissue diseases/vasculitis	Connective tissue	aggravate pain, especially in patients taking anti-inflammatory medications (steroidal and non-steroidal).
 Scleroderma leading to 	diseases and vasculitis	
_		Court
pulmonary	Osteoarthritis	Gout
Hypertension	Osteoporosis	Those with well-controlled gout should follow dietary precautions and adequate rehydration. Patients with
HypertensionUncontrolled Gout	OsteoporosisSjogren's syndrome	
HypertensionUncontrolled GoutHigher dose of steroids	Osteoporosis	Those with well-controlled gout should follow dietary precautions and adequate rehydration. Patients with
HypertensionUncontrolled Gout	OsteoporosisSjogren's syndrome	Those with well-controlled gout should follow dietary precautions and adequate rehydration. Patients with



•	Anorexia/bulimia nervosa	Stable/controlled disease	• Patients should continue taking their medicines as prescribed. Dosing regimens may need review in light
•	Substance dependence	with previous	of long fasts.
	A disorder where stopping the	history of safe fasting	 Patients should maintain their normal diet and fluid intake
	regime may cause harm		• Patients should seek advice if the condition worsens, or they develop new symptoms or adverse effects.
•	Medication dosing interval		
	shorter		Information on how to manage a patient with an eating disorder can be found here:
	than fasting hours, and		https://www.bda.uk.com/resource/ramadan-and-eating-disorders.html
	necessary to		https://freedfromed.co.uk/img/guides/Ramadan%20and%20Eating%20Disorders%20Brief%20guide_Shorte
	prevent relapse/harm		<u>ned.pdf</u>
•	Poorly controlled SMI disorders		
•	Risk of electrolyte imbalance		
	(e.g.		
	lithium) or medication out of		
	range		

Ramadan During COVID-19

Due to ongoing COVID-19, people in the Muslim community need to stay healthy and fast safely during Ramadan.

The BIMA has information on Ramadan and the safety of fasting here: <u>https://britishima.org/saferamadan/</u>

Patients with suspected COVID-19-like symptoms should be advised to follow Government and medical advice, and contact the NHS via 111. Further information can be found <u>here</u>.

In light of COVID-19, episodes of any illness should be taken seriously and may require the breaking of the fast. In this instance, particularly prolonged fever, it is important to remain hydrated. Medical attention should be sought where appropriate and patients advised to contact their GP or 111.

If a household member has COVID-19 or develops symptoms whilst fasting, they may need to break the fast and contact their GP or use the 111 online service depending on their symptoms.

Following a COVID-19 illness, patients should only restart fasting when they have fully recovered.



COVID-19 vaccination and fasting:

Vaccination of Muslim patients during Ramadan, either during or outside of fasting hours, should be able to continue as normal.

British Islamic Medical Association viewed the analysis of Islamic scholars and confirmed that having the Covid-19 vaccine does not invalidate the fast. The vaccine does not contain pork or another animal, foetal, or alcohol products – this reflects the advice of the majority of Islamic scholars that it is permissible. Please see further guidance here.

How to Prepare for Ramadan During Covid-19

Please visit the <u>SafeRamadan-2021-MCB-guidance.pdf</u> (britishima.org)

BIMA advise people to consider the concession whereby those who are more at risk if they contract COVID-19 may be excused from fasting at this time, and that missed fasts can be made up at a later date in the year.

References:

- WHO. Safe Ramadan practices in the context of the COVID-19 <u>https://apps.who.int/iris/bitstream/handle/10665/331767/WHO-2019-nCoV-Ramadan-2020.1-eng.pdf</u>
- British Islamic Medical Association. Ramadan Initiative- <u>https://www.britishima.org/ramadan-initiative/</u>
- Muslim Council of Britain. Ramadan Guidance- https://mcb.org.uk/wp-content/uploads/2022/11/MCB-Ramadan-Guidance-2022.pdf
- Muslim Council of Britain. Ramadan Health Factsheet- https://mcb.org.uk/wp-content/uploads/2020/04/MCB_Ramadan-Health-Factsheet-2020.pdf
- Diabetes Ramadan Alliance (DAR) https://www.daralliance.org/daralliance/guidelines/
- Use of SGLT2 inhibitors during Ramadan: An expert panel statementhttps://www.sciencedirect.com/science/article/pii/S016882272030718X#:~:text=Almost%20all%20these%20guidelines%20recommend,10%5D%2C%20 %5B11%5D
- Summary fasting guidelines for Diabetes during Ramadan- <u>https://www.england.nhs.uk/midlands/wp-content/uploads/sites/46/2020/11/SWBCCG-Summary-Guidance-Diabetes-Ramadan-V1.pdf</u>
- Chronic Kidney Disease and Ramadan- <u>https://www.northeastlondonhcp.nhs.uk/gps/GP%20services/General/Ramadan/CKD%20ramadan.docx</u>
- IBD Patient Panel Royal London and Mile End Hospital- https://ibdpatientpanelrlh.wixsite.com/ibdrl-meh/updates-team-contact-details
- Diabetes And Ramadan Guidance For Fasting During The Holy Month- https://www.hey.nhs.uk/patient-leaflet/diabetes-ramadan-guidance-fasting-
 https://www.hey.nhs.uk/patient-leaflet/diabetes-ramadan-guidance-fasting-